AcuCort has submitted a price and subsidy application to the Swedish price authority Tandvårds- och läkemedelsförmånsverket (TLV) regarding the company’s drug Zeqmelit®. The application is considered to be an important milestone ahead of the market introduction of Zeqmelit® in Sweden.
The application aims to give AcuCort approval for a subsidized price of the oral film Zeqmelit® in Sweden, which means that the medicine can be sold to the end consumer for a lower price and at the same time be covered by the so-called high cost protection.
As previously communicated, the application was preceded by a questionnaire study that included 426 allergy patients. The study yielded a positive outcome where, among other things, 72 percent of the patients answered that they would prefer an oral film to tablet treatment in the event of a severe allergic reaction. The survey study is considered by AcuCort to be an important basis for the application to TLV.
The company estimates that a final decision on the subsidized price can be obtained by the end of Q2, 2023, depending on the authority's timetable.
"The price and subsidy application to TLV is an important part of the marketing plan that we are following to introduce Zeqmelit® on the Swedish market. With a subsidized price, greater opportunities are opened for the drug to reach a wider market, and thus meet the great need among allergy patients for more effective administration in the treatment of acute and severe allergic reactions," says Jonas Jönmark, CEO of AcuCort.
For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
Email: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark and Norway. All in all, it strengthens the company's assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.